| Literature DB >> 30513738 |
Yingtong Cui1, Xuejuan Zhang2,3, Wen Wang4, Zhengwei Huang5, Ziyu Zhao6,7, Guanlin Wang8, Shihao Cai9, Hui Jing10, Ying Huang11, Xin Pan12, Chuanbin Wu13.
Abstract
Netilmicin (NTM) is one of the first-line drugs for lower respiratory tract infections (LRTI) therapy, but its nephrotoxicity and ototoxicity caused by intravenous injection restrict its clinical application. Dry powder inhalation (DPI) is a popular local drug delivery system that is introduced as a solution. Due to the nature of NTM hygroscopicity that hinders its direct use through DPI, in this study, L-leucine (LL) was added into NTM dry powder to reduce its moisture absorption rate and improve its aerosolization performance. NTM DPIs were prepared using spray-drying with different LL proportions. The particle size, density, morphology, crystallinity, water content, hygroscopicity, antibacterial activity, in vitro aerosolization performance, and stability of each formulation were characterized. NTM DPIs were suitable for inhalation and amorphous with a corrugated surface. The analysis indicated that the water content and hygroscopicity were decreased with the addition of LL, whilst the antibacterial activity of NTM was maintained. The optimal formulation ND₂ (NTM:LL = 30:1) showed high fine particle fraction values (85.14 ± 8.97%), which was 2.78-fold those of ND₀ (100% NTM). It was stable after storage at 40 ± 2 °C, 75 ± 5% relative humidity (RH). The additional LL in NTM DPI successfully reduced the hygroscopicity and improved the aerosolization performance. NTM DPIs were proved to be a feasible and desirable approach for the treatment of LRTI.Entities:
Keywords: dry powder inhalation; l-leucine; lower respiratory tract infection; moisture resistant; netilmicin
Year: 2018 PMID: 30513738 PMCID: PMC6321429 DOI: 10.3390/pharmaceutics10040252
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1The moisture absorption process of particles.
Composition of netilmicin (NTM) dry powder inhalations (DPIs).
| Formulation | ND0 | ND1 | ND2 | ND3 |
|---|---|---|---|---|
| NTM:LL | 100:0 | 50:1 | 30:1 | 10:1 |
Particle size of NTM DPIs (n = 3).
| Formulation | Span | |||||
|---|---|---|---|---|---|---|
| ND0 | 1.46 ± 0.04 | 3.07 ± 0.12 | 6.60 ± 0.99 | 7.56 ± 3.23 | 2.42 ± 0.01 | 1.50 ± 0.07 |
| ND1 | 1.39 ± 0.01 | 3.07 ± 0.04 | 6.05 ± 0.07 | 3.44 ± 0.04 | 2.35 ± 0.01 | 1.63 ± 0.04 |
| ND2 | 1.36 ± 0.01 | 2.89 ± 0.02 | 5.42 ± 0.04 | 3.17 ± 0.02 | 2.40 ± 0.01 | 1.44 ± 0.05 |
| ND3 | 1.36 ± 0.01 | 3.07 ± 0.01 | 6.00 ± 0.03 | 3.41 ± 0.01 | 2.38 ± 0.01 | 1.84 ± 0.03 |
Figure 2The bulk density and tap density of NTM DPIs (n = 3).
Figure 3SEM images of NTM DPIs.
Figure 4Schematic illustration of the formation mechanism of NTM DPIs.
Figure 5Powder X-ray diffraction (PXRD) patterns of raw NTM, raw l-leucine (LL), and NTM DPIs.
Figure 6Water content and hygroscopicity results of different NTM DPIs (n = 3).
Figure 7Minimum inhibitory concentrations of different NTM DPIs (n = 6).
Aerosolization performance of NTM DPIs (n = 3).
| Formulation | RD a (%) | FPF b (%) |
|---|---|---|
| ND0 | 69.3 ± 2.2 | 30.60 ± 7.56 |
| ND1 | 93.3 ± 1.7 | 64.93 ± 6.36 |
| ND2 | 98.2 ± 1.2 | 85.14 ± 8.97 |
| ND3 | 82.7 ± 1.8 | 47.82 ± 7.44 |
a RD, recovery dose; b FPF, fine particle fraction.
Figure 8The influence of a corrugated particle surface in the respiratory tract.
Aerodynamic behavior of ND2 after storage in an accelerated condition (n = 3).
| Month(s) of Storage | RD (%) | FPF (%) |
|---|---|---|
| 0 | 98.2 ± 1.2 | 85.14 ± 8.97 |
| 1 | 97.9 ± 1.6 | 83.26 ± 5.88 |
| 2 | 97.7 ± 1.4 | 84.78 ± 6.49 |
| 3 | 97.3 ± 2.0 | 83.31 ± 6.72 |